about resvinet / global-network
Key research questions can only be answered through multidisciplinary and networking approaches. Until the establishment of ReSViNET there was no international, integrated, multidisciplinary and translational research approach focused on RSV infections.
With the introduction and scaling up of vaccines against Streptococcus pneumoniae and Haemophilus influenzae type B in developing countries, the relative importance of RSV as an etiology of pediatric pneumonia becomes all the more important. Therefore, there has been an unprecedented interest in RSV research with an increasing number of studies underway and more to appear with the development of new diagnostics as well as preventive and therapeutic intervention.
In this setting, ReSViNET was founded in Utrecht, The Netherlands on January 14th, 2014 by 9 clinician scientists and Julius Clinical, an Academic Research Organization, as a fully independent research network with the mission to decrease the global burden of RSV infection. The founding members, who share many values professionally, had already been connected through research, education or other network activities.
ReSViNET is stimulating and performing research aiming to understand the burden of RSV infection, to advocate for better care for patients with RSV infection, to provide education related to RSV infection and to provide effective partnerships with relevant stakeholders.
Our Board Members are located around the globe. RSV is a cyclical illness, and our global network ensures that trials can be conducted year round, following the outbreak of the disease across continents and hemispheres. We deliver our services for clinical trials in Pediatrics as well as for trials in older adults.